Download PDF
Hamostaseologie 2021; 41(01): 048-057
DOI: 10.1055/a-1334-3259
Review Article

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Anna Falanga
1   Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
2   University of Milano-Bicocca, Department of Medicine and Surgery, Monza, Italy
,
Marina Marchetti
1   Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Francesca Schieppati
1   Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders of the hematopoietic stem cell. Classical BCR/ABL-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Thrombotic events are a major cause of morbidity and mortality in these patients. Pathogenesis of blood clotting activation involves various abnormalities of platelets, erythrocytes, and leukocytes, as well as dysfunctions of endothelial cells. Patients with MPN can be stratified in “high risk” or “low risk” of thrombosis according to established risk factors. ET and PV clinical management is highly dependent on the patient's thrombotic risk, and a risk-oriented management strategy to treat these diseases is strongly recommended. In this review, we give an overview of risk factors, pathogenesis, and thrombosis prevention and treatment in MPN.

Keywords

management of thrombosis - prevention - thrombosis - myeloproliferative neoplasms


Publication History

Received: 16 November 2020

Accepted: 08 December 2020

Article published online:
15 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    CrossrefPubMedGoogle Scholar
  • 2 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (13) 2176-2184
    CrossrefPubMedGoogle Scholar
  • 3 Hultcrantz M, Björkholm M, Dickman PW. et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018; 168 (05) 317-325
    CrossrefPubMedGoogle Scholar
  • 4 Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 2019; 19 (01) 184
    CrossrefPubMedGoogle Scholar
  • 5 Barbui T, Carobbio A, Rumi E. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014; 124 (19) 3021-3023
    CrossrefPubMedGoogle Scholar
  • 6 Marchioli R, Finazzi G, Landolfi R. et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23 (10) 2224-2232
    CrossrefPubMedGoogle Scholar
  • 7 Harrison CN, Campbell PJ, Buck G. et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353 (01) 33-45
    CrossrefPubMedGoogle Scholar
  • 8 Barbui T, Carobbio A, Cervantes F. et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115 (04) 778-782
    CrossrefPubMedGoogle Scholar
  • 9 Carobbio A, Finazzi G, Antonioli E. et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112 (08) 3135-3137
    CrossrefPubMedGoogle Scholar
  • 10 Passamonti F, Rumi E, Arcaini L. et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93 (11) 1645-1651
    CrossrefPubMedGoogle Scholar
  • 11 Barbui T, Thiele J, Passamonti F. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29 (23) 3179-3184
    CrossrefPubMedGoogle Scholar
  • 12 Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 2014; 40 (03) 348-358
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013; 162 (06) 730-747
    CrossrefPubMedGoogle Scholar
  • 14 Tefferi A, Rumi E, Finazzi G. et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27 (09) 1874-1881
    CrossrefPubMedGoogle Scholar
  • 15 Carobbio A, Thiele J, Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
    CrossrefPubMedGoogle Scholar
  • 16 Barbui T, Barosi G, Birgegard G. et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29 (06) 761-770
    CrossrefPubMedGoogle Scholar
  • 17 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95 (12) 1599-1613
    CrossrefPubMedGoogle Scholar
  • 18 Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015; 1 (01) 97-105
    CrossrefPubMedGoogle Scholar
  • 19 Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93 (09) 1412-1414
    CrossrefPubMedGoogle Scholar
  • 20 Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 21 Klampfl T, Gisslinger H, Harutyunyan AS. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369 (25) 2379-2390
    CrossrefPubMedGoogle Scholar
  • 22 Rotunno G, Mannarelli C, Guglielmelli P. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123 (10) 1552-1555
    CrossrefPubMedGoogle Scholar
  • 23 Rumi E, Pietra D, Ferretti V. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123 (10) 1544-1551
    CrossrefPubMedGoogle Scholar
  • 24 Finazzi G, Carobbio A, Guglielmelli P. et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014; 124 (16) 2611-2612
    CrossrefPubMedGoogle Scholar
  • 25 Tefferi A, Barbui T. Essential thrombocythemia and polycythemia vera: focus on clinical practice. Mayo Clin Proc 2015; 90 (09) 1283-1293
    CrossrefPubMedGoogle Scholar
  • 26 Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2 (8102): 1219-1222
    CrossrefPubMedGoogle Scholar
  • 27 Di Nisio M, Barbui T, Di Gennaro L. et al; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136 (02) 249-259
    CrossrefPubMedGoogle Scholar
  • 28 Gordeuk VR, Key NS, Prchal JT. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica 2019; 104 (04) 653-658
    CrossrefPubMedGoogle Scholar
  • 29 Marchioli R, Finazzi G, Specchia G. et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368 (01) 22-33
    CrossrefPubMedGoogle Scholar
  • 30 Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F. et al; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 2017; 102 (01) 103-109
    CrossrefPubMedGoogle Scholar
  • 31 Cortelazzo S, Finazzi G, Ruggeri M. et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332 (17) 1132-1136
    CrossrefPubMedGoogle Scholar
  • 32 Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19 (03) 617-633
    CrossrefPubMedGoogle Scholar
  • 33 Landolfi R, Di Gennaro L, Barbui T. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109 (06) 2446-2452
    CrossrefPubMedGoogle Scholar
  • 34 Tefferi A. Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. Am J Hematol 2010; 85 (02) 93-94
    PubMedGoogle Scholar
  • 35 Girodon F, Dutrillaux F, Broséus J. et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia 2010; 24 (04) 900-903
    CrossrefPubMedGoogle Scholar
  • 36 Cerquozzi S, Barraco D, Lasho T. et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 2017; 7 (12) 662
    CrossrefPubMedGoogle Scholar
  • 37 Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019; 3 (11) 1729-1737
    CrossrefPubMedGoogle Scholar
  • 38 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90 (02) 162-173
    CrossrefPubMedGoogle Scholar
  • 39 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
    CrossrefPubMedGoogle Scholar
  • 40 Barbui T, Vannucchi AM, Buxhofer-Ausch V. et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015; 5: e369
    CrossrefPubMedGoogle Scholar
  • 41 Guy A, Gourdou-Latyszenok V, Le Lay N. et al. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 2019; 104 (01) 70-81
    CrossrefPubMedGoogle Scholar
  • 42 Ataga KI, Kutlar A, Kanter J. et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017; 376 (05) 429-439
    CrossrefPubMedGoogle Scholar
  • 43 Rosti V, Villani L, Riboni R. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2013; 121 (02) 360-368
    CrossrefPubMedGoogle Scholar
  • 44 Marchetti M, Tartari CJ, Russo L. et al. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 2014; 89 (01) 68-73
    CrossrefPubMedGoogle Scholar
  • 45 Marchetti M, Castoldi E, Spronk HM. et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112 (10) 4061-4068
    CrossrefPubMedGoogle Scholar
  • 46 Landolfi R, Marchioli R, Kutti J. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (02) 114-124
    CrossrefPubMedGoogle Scholar
  • 47 Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90 (09) 3370-3377
    CrossrefPubMedGoogle Scholar
  • 48 Najean Y, Rain JD. The French Polycythemia Study Group. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997; 89 (07) 2319-2327
    CrossrefPubMedGoogle Scholar
  • 49 Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34 (01) 17-23
    PubMedGoogle Scholar
  • 50 Finazzi G, Caruso V, Marchioli R. et al; ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105 (07) 2664-2670
    CrossrefPubMedGoogle Scholar
  • 51 Vannucchi AM, Kiladjian JJ, Griesshammer M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372 (05) 426-435
    CrossrefPubMedGoogle Scholar
  • 52 Passamonti F, Griesshammer M, Palandri F. et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 2017; 18 (01) 88-99
    CrossrefPubMedGoogle Scholar
  • 53 Kiladjian J-J, Zachee P, Hino M. et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 2020; 7 (03) e226-e237
    CrossrefPubMedGoogle Scholar
  • 54 Gisslinger H, Klade C, Georgiev P. et al; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 2020; 7 (03) e196-e208
    CrossrefPubMedGoogle Scholar
  • 55 Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC. et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 2014; 93 (12) 2037-2043
    CrossrefPubMedGoogle Scholar
  • 56 Rocca B, Tosetto A, Betti S. et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136 (02) 171-182
    CrossrefPubMedGoogle Scholar
  • 57 Gisslinger H, Gotic M, Holowiecki J. et al; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121 (10) 1720-1728
    CrossrefPubMedGoogle Scholar
  • 58 Birgegård G, Besses C, Griesshammer M. et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica 2018; 103 (01) 51-60
    CrossrefPubMedGoogle Scholar
  • 59 Yacoub A, Mascarenhas J, Kosiorek H. et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 2019; 134 (18) 1498-1509
    CrossrefPubMedGoogle Scholar
  • 60 Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014; 371 (02) 188-189
    CrossrefPubMedGoogle Scholar
  • 61 Guglielmelli P, Pacilli A, Rotunno G. et al; AGIMM Group. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 2017; 129 (24) 3227-3236
    CrossrefPubMedGoogle Scholar
  • 62 Rumi E, Boveri E, Bellini M. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 2017; 8 (60) 101735-101744
    CrossrefPubMedGoogle Scholar
  • 63 Buxhofer-Ausch V, Gisslinger H, Thiele J. et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 2012; 87 (07) 669-672
    CrossrefPubMedGoogle Scholar
  • 64 Buxhofer-Ausch V, Gisslinger B, Schalling M. et al. Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. Br J Haematol 2017; 179 (01) 166-169
    CrossrefPubMedGoogle Scholar
  • 65 Finazzi G, Carobbio A, Thiele J. et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26 (04) 716-719
    CrossrefPubMedGoogle Scholar
  • 66 Campbell PJ, Bareford D, Erber WN. et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27 (18) 2991-2999
    CrossrefPubMedGoogle Scholar
  • 67 Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J 2018; 8 (11) 104
    CrossrefPubMedGoogle Scholar
  • 68 Sekhar M. Prevention and management of thrombosis in myeloproliferative neoplasms. Clin Adv Hematol Oncol 2017; 15 (03) 178-181
    PubMedGoogle Scholar
  • 69 De Stefano V, Za T, Rossi E. et al; GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93 (03) 372-380
    CrossrefPubMedGoogle Scholar
  • 70 De Stefano V, Ruggeri M, Cervantes F. et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 2016; 30 (10) 2032-2038
    CrossrefPubMedGoogle Scholar
  • 71 Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F. et al; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 2015; 94 (06) 911-918
    CrossrefPubMedGoogle Scholar
  • 72 Barbui T, De Stefano V, Falanga A. et al. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper. Blood Cancer J 2019; 9 (08) 61
    CrossrefPubMedGoogle Scholar
  • 73 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 74 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 75 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 76 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e96S
    CrossrefPubMedGoogle Scholar
  • 77 Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. J Thromb Thrombolysis 2018; 45 (01) 106-113
    CrossrefPubMedGoogle Scholar
  • 78 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
    CrossrefPubMedGoogle Scholar
  • 79 Lee AY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 80 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 81 Finazzi G, De Stefano V, Barbui T. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J 2018; 8 (07) 64
    CrossrefPubMedGoogle Scholar
  • 82 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 83 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 84 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 85 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. J Cardiovasc Pharmacol Ther 2015; 20 (05) 490-500
    CrossrefPubMedGoogle Scholar
  • 87 Raskob GE, van Es N, Segers A. et al; Hokusai-VTE Investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016; 3 (08) e379-e387
    CrossrefPubMedGoogle Scholar
  • 88 Ianotto JC, Couturier MA, Galinat H. et al. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 2017; 106 (04) 517-521
    CrossrefPubMedGoogle Scholar
  • 89 Kaifie A, Kirschner M, Wolf D. et al; Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18
    CrossrefPubMedGoogle Scholar
  • 90 Curto-Garcia N, Doyle AJ, Breen KA. et al. Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol 2020; 189 (03) e79-e81
    CrossrefPubMedGoogle Scholar
  • 91 Serrao A, Breccia M, Napolitano M. et al. A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms. Am J Hematol 2020; 95 (12) E329-E332
    CrossrefPubMedGoogle Scholar
  • 92 De Grandis M, Cambot M, Wautier MP. et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood 2013; 121 (04) 658-665
    CrossrefPubMedGoogle Scholar
  • 93 Klatt C, Krüger I, Zey S. et al. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. J Clin Invest 2018; 128 (09) 3906-3925
    CrossrefPubMedGoogle Scholar
  • 94 Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91 (02) 169-175
    PubMedGoogle Scholar
  • 95 Edelmann B, Gupta N, Schnoeder TM. et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128 (10) 4359-4371
    CrossrefPubMedGoogle Scholar
  • 96 Wolach O, Sellar RS, Martinod K. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 2018; 10 (436) eaan8292
    CrossrefPubMedGoogle Scholar